Cyclin D1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study

Area of Science:

• Endocrinology
• Oncology
• Molecular Biology

Background:

• The cyclin D1 (PRAD1) oncogene is implicated in parathyroid adenomas through rearrangement with the PTH gene.
• Heterogeneity in rearrangement breakpoints makes precise quantification of cyclin D1 deregulation challenging.
• Cyclin D1 protein overexpression is a consistent outcome of gene rearrangements and a marker for its pathogenic role.

Purpose of the Study:

• To comprehensively assess cyclin D1 protein expression in parathyroid adenomas.
• To identify the prevalence of cyclin D1 overexpression in parathyroid tumors.
• To correlate cyclin D1 expression with clinical parameters like adenoma mass and PTH levels.

Main Methods:

• Microwave-enhanced immunohistochemistry was used to detect cyclin D1 protein.
• Affinity-purified cyclin D1 polyclonal antiserum was employed for detection.
• Expression was analyzed in 65 parathyroid adenomas, 51 normal glands, and 4 parathyroid carcinomas.

Main Results:

• Eighteen percent (12/65) of parathyroid adenomas exhibited diffuse nuclear cyclin D1 staining.
• Normal parathyroid glands showed negative or minimal scattered cyclin D1 staining.
• Two of four parathyroid carcinomas displayed strong nuclear cyclin D1 staining.

Conclusions:

• Cyclin D1 overexpression is a significant feature in 18% of parathyroid adenomas, indicating a broader pathogenic role than previously recognized.
• Cyclin D1 overexpression is a common feature in parathyroid adenomas, not limited to large or symptomatic tumors.
• The presence of cyclin D1 overexpression in parathyroid carcinomas suggests its potential importance in these malignancies as well.